Chimeric Antigen Receptor T Cell Therapy Targeting Nkg2d Ligand

e14523Background: Chimeric antigen receptor T cell (CAR-T) therapy is promising immunotherapy for cancer. While CAR-T therapy has shown encouraging results against CD19 in acute lymphoblastic lymphoma and other hematologic malignancies, CAR-T therapy targeting solid tumors is having problem with shortage of appropriate target antigens. NKG2D ligand (NKG2DL) is a ligand of NKG2D, which is expressed mainly on NK and γδ T cells, could be an attractive target of CAR-T therapy. NKG2DL such as MICA, MICB, and ULBP1 (UL16 binding protein 1) to ULBP3 are reported to be expressed on several kinds of tumors. Expression of MICA/MICB on tumor cells are reported to correlate with poor prognosis. Here we demonstrate that co-expressions of ULBP1 in cancer and NKG2D in peripheral blood mononuclear cells are associated with better prognosis in gastric cancer. For further analysis, we are investigating whether NKG2DL is appropriate target and which one among NKG2DL is able to be a target for the CAR-T therapy. Methods: We ...